Return to homepagePandemic Pact

Inhibition of SARS-CoV-2 Polymerase

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 202012GSM

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $788,676.75

  • Funder

    Canadian Institutes of Health Research (CIHR)

  • Principal Investigator

    N/A

  • Research Location

    Canada

  • Lead Research Institution

    University of Alberta

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The current global pandemic due to SARS-CoV-2 has highlighted the need for antiviral treatments. A good target for these therapies has been the RNA-Dependent RNA Polymerase of the virus. Using the baculovirus expression system, the Gotte lab has been able to express the polymerase complex, allowing us to explore potential inhibitors. Using polyacrylamide gel electrophoresis (PAGE), I will be screening potential inhibitors. I will be determining the concentration required to inhibit 50% of activity and also exploring the specificities of the inhibitors. If there is a compound that shows promise, we will study it in cell culture as well as determine the mechanism of action. I believe that my research will contribute significantly to the fight against coronavirus.